Q1 Earnings Forecast for CMPS Issued By HC Wainwright

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Compass Pathways in a research note issued on Wednesday, March 25th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($0.35) for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.66) EPS and FY2027 earnings at ($0.96) EPS.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59).

CMPS has been the topic of a number of other reports. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Morgan Stanley reduced their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Compass Point set a $15.00 target price on Compass Pathways in a research note on Thursday, February 12th. Finally, Canaccord Genuity Group reduced their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.63.

Compass Pathways Stock Down 4.8%

Shares of NASDAQ:CMPS opened at $5.37 on Friday. The company has a quick ratio of 1.23, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The stock has a market cap of $515.63 million, a price-to-earnings ratio of -1.74 and a beta of 1.90. The business’s 50 day moving average is $6.66 and its 200 day moving average is $6.30. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $8.90.

Institutional Trading of Compass Pathways

A number of large investors have recently bought and sold shares of CMPS. Flax Pond Capital LLC purchased a new position in shares of Compass Pathways during the 4th quarter valued at $364,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways during the 4th quarter worth $47,000. Seven Fleet Capital Management LP purchased a new stake in Compass Pathways in the 4th quarter worth about $276,000. Corient Private Wealth LLC raised its stake in Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after acquiring an additional 1,200 shares during the period. Finally, XTX Topco Ltd raised its stake in Compass Pathways by 457.5% in the 4th quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock valued at $392,000 after acquiring an additional 46,600 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

More Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a very high $70 price target, signaling a strong long‑term bullish case and large implied upside versus the current share price. (This supports investor optimism even as near‑term forecasts were adjusted.)
• Neutral Sentiment: Upcoming FDA review meeting for COMP360 is a potential binary catalyst — outcomes or guidance from that meeting could swing sentiment materially in either direction. Compass Pathways (CMPS): What will come out of FDA review meeting for depression drug candidate COMP360?
• Neutral Sentiment: Canaccord cut its price target from $20 to $18 but kept a “Buy” rating — a modest downgrade that still implies significant upside from current levels. Canaccord target cut report
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to ($1.66) from ($1.36) and cut FY2027 to ($0.96) (previously $0.72), and issued lower quarterly EPS estimates across 2026–2027 — firms’ reduced profit outlook increases short‑term pressure on the share price.
• Negative Sentiment: Morgan Stanley trimmed its price target to $16, which reduces near‑term upside and may prompt short‑term selling. Morgan Stanley Lowers Compass Pathways (NASDAQ:CMPS) Price Target to $16.00
• Negative Sentiment: Recent earnings (reported 3/24) missed estimates (EPS -$1.00 vs. consensus -$0.41), reinforcing concerns on near‑term profitability and contributing to downward pressure on the stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.